Motor Cortex Stimulation for the Treatment of Chronic Facial, Upper Extremity, and Throat Pain.

Inclusion criteria

• ✓. Males and females who are greater than 18 years of age.
• ✓. Subject has a diagnosis of chronic pain involving the face, upper extremity, or throat, as determined by a review of medical records, history and physical examination. The types of chronic pain eligible for the study are:
• ✓. Facial pain, including trigeminal neuralgia Type 1, trigeminal neuralgia Type 2, trigeminal neuropathic pain, trigeminal deafferentation pain, symptomatic trigeminal neuralgia, and postherpetic neuralgia.
• ✓. Complex Regional Pain Syndrome (Types I and II) involving the arm.
• ✓. Both chronic and episodic forms of refractory Glossopharyngeal Neuralgia (GN).
• ✓. Deafferentation of the cervical spine leading to pain of the upper extremity.
• ✓. Central pain syndromes resulting from a prior cerebrovascular insult occurring at least 5 years prior to the study.
• ✓. Subject determined to be treatment-resistant for at least one year prior to the Screening Visit as demonstrated by clinical evidence (determined by review of medical records and discussion with referring pain specialist, anesthesiologist, or neurologist treating chronic pain). The patient must not have responded to treatment with three adequate regimens of medication including one in each of the following categories: antiepileptic drugs, opioids, and antidepressant medications. The trial period for each medication should be at least four weeks, and the two trials must be within the previous 5 years.